Review Article
Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphomas
Table 2
Studies on high-dose therapy and autologous stem cell transplantation in PTCL as first-line therapy.
| (a) Retrospective data |
| | Author | Year | | Age | Histologies (WHO) | IPI | High-dose regimen | Status at Tx | DFS/EFS/ PFS/RFS | OS | Followup (months) | Comment |
| | Rodríguez et al. [38] | 2007 | 19 | 46 | AITL 100% | aaIPI
0/1 37%
2/3 63% | BEAM/BEAC (79%) | CR1 42%
PR1 26% | 55% (3 y) | 60% (3 y) | 25 | 15/19 transplanted 1.line |
| | Rodríguez et al. [39] | 2007 | 74 | 46 | PTCLu 50%
ALCL 31%
AITL 11%
Other 7% | aaIPI
0/1 35%
2/3 65% | BEAM/BEAC (91%) | No data | 63% (5 y) | 68% (5 y) | 67 | |
| | Feyler et al. [40] | 2007 | 64 | 45 | PTCLu 47%
ALCL 31%
AITL 8%
Other 14% | 0/1 34%
2 11%
3 11%
4/5 2%
Unknown 42% | Diverse | CR1 48%
PR1 23% | 50% (3 y) | 53% (3 y) | 48 | Incl. CTCL, T-cell leukemia/lymphoma 46/64 transplanted 1.line |
| | Kyriakou et al. [41] | 2008 | 146 | 53 | AITL 100% | No data | BEAM (74%) | CR1 33%
PR 36% | 49% (4 y) | 59% (4 y) | 31 | 101/146 transplanted 1.line |
| | Prochazka et al. [42] | 2009 | 18 | 59 | PTCLu 56%
ALCL 39%
AITL 6% | 0/1 28%
2 28%
≥3 44% | BEAM | No data | 52% (2 y) | 71% (2 y) | 26 | |
| | Numata et al. [43] | 2010 | 39 | 53 | PTCLu 31%
AITL 28%
ALCL 23%
NK/T 18% | aaIPI
0/1 33%
2/3 59%
Unknown 8% | MCEC ()
TBI-based () | CR1 69% | 61% (5 y) | 62% (5 y) | 78 | 23/39 transplanted 1.line |
|
|
Studies including both patients receiving HDT-autoSCT 1.line and 2.line are listed in the table representing the predominant group.
|
| (b) Prospective data |
| | Author | Year | | Age | Histologies (WHO) | IPI | High-dose regimen | Status at Tx | Tx rate | DFS/EFS/ PFS | OS | Followup (months) | Comment |
| | Mounier et al. [44] | 2004 | 28 | 36 | PTCLu 56%
Precursor 44% | 0/1 25%
≥2 75% | BEAM/CBV | CR 100% | No data | 44% (5 y) | 54% (5 y) | 78′ | Incl. precursor T-cell lymphoma |
| | Nickelsen et al. [45] | 2009 | 33 | 48 | 39%
PTCLu 33%
AITL 12%
Other 16% | aaIPI
0/1 9%
2/3 91% | MegaCHOEP | CR 49%
PR 6%
after therapy | 67% | 26% (3 y) | 45% (3 y) | 53 | Sequential HDT-autoSCT Subgroup analysis |
| | Corradini et al. [46] | 2006 | 62 | 43 | PTCLu 45%
ALK+ ALCL 30%
AITL 16%
Other 9% | 0/1 19%
≥2 71% | Mito/Mel or BEAM | CR 56%
PR 16% | 71% | 30% (12 y) | 34% (12 y) | 76 | Incl. |
| | Rodríguez et al. [47] | 2007 | 26 | 44 | PTCLu 42%
31%
AITL 27% | aaIPI
0/1 28%
2/3 72% | BEAM | CR 65%
PR 8% | 73% | 53% (3 y) | 73% (3 y) | 35’ | No 13/26 transplanted 1.line |
| | Mercadal et al. [48] | 2008 | 41 | 47 | PTCLu 49%
AITL 29%
HSTL 5%
NK/T 5%
Other 12% | 0/1 22%
2 32%
3 22%
4/5 24% | BEAM/BEAC | CR 49%
PR 10% | 41% | 30% (4 y) | 39% (4 y) | 38 | No |
| | Reimer et al. [49] | 2009 | 83 | 47 | PTCLu 39%
AITL 33%
16%
Other 12% | aaIPI
0/1 49%
2/3 51% | Cy/TBI | CR 47%
PR 24% | 66% | 36% (3 y) | 48% (3 y) | 33 | No |
| | D'Amore et al. [50] | 2009 | 160 | 57 | PTCLu 39%
AITL 19%
19%
HSTL 13%
Other 10% | 0/1 18%
≥2 72% | BEAM | No data | 71% | 49% (3 y) | 57% (3 y) | 45 | No |
|
|
